β-Adrenergic receptor blockade in chronic heart failure

Circulation

Volumn 101, Issue 5, 2000, Pages 558-569

  Bristow, Michael R ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Drugs; Heart failure; Receptors, adrenergic, beta

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BUCINDOLOL; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; METOPROLOL; NEBIVOLOL; PROPRANOLOL;

BETA ADRENERGIC RECEPTOR BLOCKING; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG RECEPTOR BINDING; HEART FAILURE; HEART FUNCTION; HUMAN; PRIORITY JOURNAL; RECEPTOR AFFINITY; REVIEW; SIGNAL TRANSDUCTION;

EID: 0034620523     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.101.5.558     Document Type: Review

References (117)

1. Eichhorn EJ, Bristow MR. Medical therapy can improve the biologic properties of the chronically failing heart: a new era in the treatment of heart failure. Circulation. 1996;94:2285-2296.
2. Stephen SA. Unwanted effects of propranolol. Am J Cardiol. 1966;18: 463-472.
3. Epstein SE, Braunwald E. The effect of beta adrenergic blockade on patterns of urinary sodium excretion: studies in normal subjects and in patients with heart disease. Ann Intern Med. 1968;65:20-27.
4. Swedberg K, Viquerat C, Rouleau JL, Roizen M, Atherton B, Parmley WW, Chaterjee K. Comparison of myocardial catecholamine balance in chronic congestive heart failure and in angina pectoris without heart failure. Am J Cardiol. 1984;54:783-786.
5. Hasking GJ, Esler MD, Jennings GL, Burton D, Korner PI. Norepinephrine spillover to plasma in patients with chronic congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity. Circulation. 1986;73:615-621.
6. Haber HL, Christopher LS, Gimple LW, Bergin JD, Subbiah ME, Jayaweera AR, Powers ER, Feldman MD. Why do patients with congestive heart failure tolerate the initiation of β-blocker therapy? Circulation. 1993;88:1610-1619.
7. Goldsmith SR, Francis GS, Cohn JN. Norepinephrine infusions in congestive heart failure. Am J Cardiol. 1985;56:802-804.
8. Bristow MR, Minobe W, Rasmussen R, Larrabee P, Skerl L, Klein JW, Anderson FL, Murray J, Mestroni L, Karwande SV, Fowler M, Ginsburg R. β-Adrenergic neuroeffector abnormalities in the failing human heart are produced by local rather than systemic mechanisms. J Clin Invest. 1992;89:803-815.
9. Kaye DM, Lefkovits J, Jennings GL, Bergin P, Broughton A, Esler D. Adverse consequences of high sympathetic nervous activity in the failing human heart. J Am Coll Cardiol. 1995;26:1257-1263.
10. 1-receptor downregulation in heart failure. Circ Res. 1986;59:297-309.
11. 2-adrenoceptors in both atria and ventricles in severe congestive cardiomyopathy. J Cardiovasc Pharmacol. 1986;8:1235-1242.
12. Bristow MR. Changes in myocardial and vascular receptors in heart failure. J Am Coll Cardiol. 1993;22(suppl A):61A-71A.
13. 1-selective and nonselective β-adrenergic receptor blockade on cardiac sympathetic activity in congestive heart failure. Circulation. 1996;94:353-358.
14. 3-adrenoceptor in the human heart. J Clin Invest. 1996;98: 556-562.
15. Kaumann AJ, Molenaar P. Modulation of human cardiac function through 4 beta-adrenergic populations. Naunyn Schmiedebergs Arch Pharmacol. 1997;355:667-681.
16. Mann DL, Kent RL, Parsons B, Cooper G IV. Adrenergic effects on the biology of the adult mammalian cardiocyte. Circulation. 1992;85: 790-804.
17. b1-adrenergic receptor. J Am Coll Cardiol. 1998;31(suppl A):177A. Abstract.
18. 1-adrenergic receptor transgenic mice. Proc Natl Acad Sci U S A 1999;96:7059-7064.
19. sαa overexpression. Circ Res. 1996;78:517-524.
20. αq overexpression induces cardiac contractile failure in mice. Proc Natl Acad Sci U S A. 1997;94:8121-8126.
21. Geng YJ, Ishikawa Y, Vatner DE, Wagner TE, Bishop SP, Vatner SF, Homey CJ. Overexpression of Gsα accelerates programmed death (apoptosis) of myocardiocytes in transgenic mice. Circulation. 1996; 94(suppl I):I-1640. Abstract.
22. Communal C, Singh K, Pimental DR, Colucci WS. Norepinephrine stimulates apoptosis in adult rat ventricular myocytes by activation of the β-adrenergic receptor. Circulation. 1998;98:1329-1334.
23. 2-adrenergic receptors on cardiac myocyte apoptosis: role of a pertussis-toxin sensitive G protein. Circulation. 1999;100:2210-2212.
24. 2-adrenergic receptor overexpression in mouse hearts: critical role for expression level. Circulation. In press.
25. 1B-adrenergic receptor in transgenic mice induces cardiac hypertrophy. Proc Natl Acad Sci U S A. 1994;91:10109-10113.
26. Ungerer M, Parruti G, Bohm M, Puzicha M, DeBlasi A, Erdmann E, Lohse MJ. Expression of β-arrestins and β-adrenergic receptor kinases in the failing human heart. Circ Res. 1994;74:206-213.
27. Tan LB, Benjamin IJ, Clark WA. β-adrenergic receptor desensitization may serve a cardioprotective role. Cardiovasc Res. 1992;26:608-614.
28. Bristow MR. The adrenergic nervous system in heart failure. N Engl J Med. 1984;311:850-851.
29. Bristow MR, Kantrowitz NE, Ginsburg R, Fowler MB. β-Adrenergic function in heart muscle disease and heart failure. J Mol Cell Cardiol. 1985;17(suppl 2):41-52.
30. Fowler MB, Bristow MR. Rationale for beta-adrenergic blocking drugs in cardiomyopathy. Am J Cardiol. 1985;55:D120-D124.
31. Dunlop D, Shanks RG. Selective blockade of adrenoceptive beta receptors in the heart. Br J Pharmacol Chemother. 1968;32:201-218.
32. Bristow MR, Sherrod TR, Green RD. Analysis of beta receptor drug interactions in isolated rabbit atrium, aorta, stomach and trachea. J Pharmacol Exp Ther: 1970;171:52-61.
33. Kobilka BK, Dixon RAF, Frielle T, Dohlman HG, Bolanowski MA, Sigal IS, Yang-Feng TL, Francke U, Caron MG, Lefkowitz RJ. cDNA for the human beta 2-adrenergic receptor: a protein with multiple membrane-spanning domains and encoded by a gene whose chromosomal location is shared with that of the receptor for platelet-derived growth factor. Proc Natl Acad Sci U S A. 1987;84:46-50.
34. 1-adrenergic receptor. Proc Natl Acad Sci U S A. 1987;84:7920-7924.
35. 3-adrenergic receptor. Science. 1989;245:1118-1121.
36. Waagstein F, Hjalmarson Å, Varnauskas E, Wallentin I. Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J. 1975;37:1022-1036.
37. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353:9-13.
38. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:2001-2006.
39. Richards DA, Prichard BNC. Clinical pharmacology of labetalol. Br J Clin Pharmacol. 1979;8:89S-93S.
40. Johnson LL, Cubbon J, Escala E, Sciacca R, Ramanathan KB, Berger H, Jones RH. Hemodynamic effects of labetalol in patients with combined hypertension and left ventricular failure. J Cardiovasc Pharmacol. 1988; 12:350-356.
41. Wisenbaugh T, Katz I, Davis J, Essop R, Skoularigis J, Middlemost S, Rothlisberger C, Skudicky D, Sareli P. Long-term (3 month) effects of a new beta-blocker (nebivolol) on cardiac performance in dilated cardiomyopathy. J Am Coll Cardiol. 1993;21:1094-1100.
42. Uhlir O, Dvorak I, Gregor P, Malek I, Spinarova L, Vojacek J, Van Nueten L. Nebivolol in the treatment of cardiac failure: a double-blind controlled clinical trial. J Card Fail. 1997;3:271-276.
43. 1adrenergic antagonist. J Cardiovasc Pharmacol. 1988;11:552-563.
44. Cockcroft JR, Chowienczyk PJ, Brett SE, Chen CPL-H, Dupont AG, Van Nueten L, Wooding SJ, Ritter JM. Nebivolol vasodilates human forearm vasculature: evidence for an L-arginine/NO-dependent mechanism. J Pharmacol Exp Ther. 1995;274:1067-1071.
45. Bristow MR, Abraham WT, Gilbert EM, Yoshikawa T, Port JD. Relationships between carvedilol stereoisomer plasma concentrations and β-receptor occupancies in subjects with chronic heart failure in the Multicenter Oral Carvedilol Heart Failure Assessment (MOCHA) trial. Eur Heart J. 1996;17:135. Abstract.
46. Yoshikawa T, Port JD, Asano K, Chidiak P, Bouvier M, Dutcher D, Roden RL, Minobe W, Trammel KD, Bristow MR. Cardiac adrenergic receptor effects of carvedilol. Eur Heart J. 1996:17(suppl B):B8-B16.
47. Bristow MR, Abraham WT, Yoshikawa T, White M, Hattler B, Crisman T, Lowes B, Larrabee P, Gilbert M. Second and third beta blocking agents in the treatment of chronic heart failure. Cardiovasc Drugs Ther. 1997;11:291-296.
48. Hershberger RE, Wynn JR, Sundberg L, Bristow MR. Mechanism of action of bucindolol in human ventricular myocardium. J Cardiovasc Pharmacol. 1990;15:959-967.
49. Deitchman D, Perhach JL, Snyder RW. β-Adrenoceptor and cardiovascular effects of MJ 13105 (bucindolol) in anesthetized dogs and rats. Eur J Pharmacol. 1980;61:263-277.
50. Rimele TJ, Aarhus LL, Lorenz RR, Rooke TW, Van Houtte PM. Pharmacology of bucindolol in isolated canine vascular smooth muscle. J Pharmacol Exp Ther. 1984;231:317-325.
51. Gilbert EM, Anderson JL, Deitchman D, Yanowitz FG, O'Connell JB, Renlund DG, Bartholomew M, Mealey PC, Larrabee P, Bristow MR. Chronic β-blocker-vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy: a double-blind, randomized study of bucindolol versus placebo. Am J Med. 1990;88:223-229.
52. Bristow MR, Larrabee P, Minobe W, Roden R, Skerl L, Klein J, Handwerger D, Port JD, Müller-Beckman B. Receptor pharmacology of carvedilol in the human heart. J Cardiovasc Pharmacol. 1992;19(suppl 1):S68-S80.
53. b-blocking agents in chronic heart failure. Clin Cardiol. 1998;21:I-3-I-13.
54. Sederberg J, Wichman SE, Lindenfeld J, Lowes B, Shakar S, Roden R, Bristow MR. Bucindolol has no intrinsic sympathomimetic activity in nonfailing human ventricular preparations. J Am Coll Cardiol. In press.
55. Lowes BD, Chidiac P, Olsen S, Port JD, Bouvier M, Gilbert EM, Bristow MR. Clinical relevance of inverse agonism and guanine nucleotide modulatable binding properties of β-adrenergic receptor blocking agents. Circulation. 1994;90(suppl I):I-543. Abstract.
56. Gilbert EM, Abraham WT, Olsen S, Hattler B, White M, Mealy P, Larrabee P, Bristow MR. Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation. 1996;94: 2817-2825.
57. Bristow MR. Mechanism of action of beta-blocking agents in heart failure. Am J Cardiol. 1997:80:26L-40L.
58. Metra M, Nodari S, Garbellini M, Boldi E, Rosselli F, Zanini R, Dei Cas L. Comparative effects of metoprolol and carvedilol on resting and peak exercise hemodynamics and functional capacity in patients with chronic heart failure. Circulation. 1997;96(suppl I):I-578. Abstract.
59. Kukin ML, Charney RH, Levy DK, Buchholz-Varley C, Ocampo ON, Eng C. Prospective, randomized comparison of effect of long-term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction, and oxidative stress in heart failure. Circulation. 1999;99: 2645-2651.
60. Eichhorn EJ, Bedotto JB, Malloy CR, Hatfield B, Deitchman D, Brown M, Willard JE, Grayburn PA. Effect of beta-adrenergic blockade on myocardial function and energetics in congestive heart failure: improvements in hemodynamic, contractile, and diastolic performance with bucindolol. Circulation. 1990;82:473-483.
61. Eichhorn EJ, Heesch CM, Barnett JH, Alvarez LG, Fass SM, Grayburn PA, Hatfield BA, Marcoux LG, Malloy CR. Effect of metoprolol on myocardial function and energetics in patients with non-ischemic dilated cardiomyopathy: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol. 1994;24:1310-1320.
62. Lechat P, Escolano S, Golmard JL, Lardoux H, Witchitz S, Henneman JA, Maisch B, Hetzel M, Jaillon P, Boissel J-P, Mallet A. Prognostic value of bisoprolol-induced hemodynamic effects in heart failure during the Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation. 1997; 96:2197-2205.
63. Hall SA, Cigarroa CG, Marcoux L, Risser RC, Grayburn PA, Eichhorn EJ. Time course of improvement in left ventricular function, mass, and geometry in patients with congestive heart failure treated with β-adrenergic blockade. J Am Coll Cardiol. 1995;25:1154-1161.
64. Quaife RA, Gilbert EM, Christian PE, Datz FL, Mealey PC, Volkman K, Olsen SL, Bristow MR. Effects of carvedilol on systolic and diastolic left ventricular performance in idiopathic dilated cardiomyopathy. Am J Cardiol. 1996;78:779-784.
65. Doughty RN, Whalley GA, Gamble G, MacMahon S, Sharpe N, for the Australia-New Zealand Heart Failure Research Collaborative Group. Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. J Am Coll Cardiol. 1997; 29:1060-1066.
66. Lowes BD, Gill EA, Abraham WT, Larrabee JR, Robertson AD, Bristow MR, Gilbert EM. The effect of carvedilol on left ventricular mass, chamber geometry and mitral regurgitation in chronic heart failure. Am J Cardiol. 1999;83:1201-1205.
67. Gaffney TE, Braunwald MD. Importance of the adrenergic nervous system in the support of circulatory function in patients with congestive heart failure. Am J Med. 1963;34:320-324.
68. Armstrong PW, Chiong MA, Parker JO. Effects of propranolol on the hemodynamic, coronary sinus blood flow and myocardial metabolic response to atrial pacing. Am J Cardiol. 1977;40:83-89.
69. Talwar KK, Bhargava B, Upasani PT, Verma S, Kamlakar T, Chopra P. Hemodynamic predictors of early intolerance and long-term effects of propranolol in dilated cardiomyopathy. J Card Fail. 1996;2:273-277.
70. Eichhorn EJ, Bristow MR. Practical guidelines for initiation of beta-adrenergic blockade in patients with chronic heart failure. Am J Cardiol. 1997;79:794-798.
71. 2-receptor agonist: a human in vivo study. Circulation. 1999;99:2402-2407.
72. Di Lenarda A, Gilbert EM, Olsen SL, Mealey PC, Bristow MR. Acute hemodynamic effects of carvedilol versus metoprolol in idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 1991;17:142A. Abstract.
73. Neugebauer G, Akpan W, Kaufmann B, Reiff K. Stereoselective disposition of carvedilol on man after intravenous and oral administration of the racemic compound. Eur J Clin Pharmacol. 1990;38:S108-S111.
74. Ruffolo RR, Gellai M, Hieble JP, Willette RN, Nichols AJ. The pharmacology of carvedilol. Eur J Clin Pharmacol. 1990;38:S82-S88.
75. Basu S, Senior R, Raval U, van der Does R, Bruckner T, Lahiri A. Beneficial effects of intravenous and oral carvedilol treatment in acute myocardial infarction: a placebo-controlled, randomized trial. Circulation. 1997;96:183-191.
76. Bristow MR, Gilbert EM. Improvement in cardiac myocyte function by biologic effects of medical therapy: a new concept in the treatment of heart failure. Eur Heart J. 1995;16(suppl F):20-31.
77. Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE, Kubo SH, Narahara KA, Ingersoll H, Krueger S, Young S. Shusterman N. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation. 1996;94:2807-2816.
78. Waagstein F, Bristow MR, Swedberg K, Camerini F, Fowler MB, Johnson M, Silver MA, Gilbert EM, Hjalmarson Å. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet. 1993;342: 1441-1446.
79. Sandberg A, Blomqvist I, Jonsson UE, Lundborg P. Pharmacokinetic and pharmacodynamic properties of a new controlled-release formulation of metoprolol: a comparison with conventional tablets. Eur J Clin Pharmacol. 1988;33(suppl):S9-S14.
80. Reeves RA, Boer WH, DeLeve WH, Leenen FH. Beta-blockade disappearance rate predicts beta-adrenergic hypersensitivity. Clin Pharmacol Ther. 1989;46:279-290.
81. Bristow MR, O'Connell JB, Gilbert EM, French WJ, Leatherman G, Kantrowitz NE, Orie J, Smucker M, Marshall G, Kelly P, Deitchman D, Anderson JL, for the Bucindolol Investigators. Dose-response of chronic β-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Circulation. 1994;89:1632-1642.
82. The BEST Steering Committee. Design of the Beta-Blocker Evaluation Survival Trial (BEST). Am J Cardiol. 1995;75:1220-1223.
83. CIBIS Investigators and Committees. A randomized trial of beta-blockade in heart failure: the Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation. 1994;90:1765-1773.
84. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293-302.
85. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH. Effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 1996;334:1349-1355.
86. Olsen SL, Gilbert EM, Renlund DG, Mealey PC, Taylor DO, Yanowitz FD, Bristow MR. Carvedilol improves left ventricular function and symptoms in heart failure: a double-blind randomized study. J Am Coll Cardiol. 1995;25:1225-1231.
87. Krum H, Sakner-Bernstein JD, Goldsmith RL, Kukin ML, Schwartz B, Penn J, Medina N, Yushak M, Horn E, Katz SD, Levin HR, Neuberg GW, DeLong G, Packer M. Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure. Circulation. 1995;92:1499-1506.
88. Packer M, Colucci WS, Sackner-Bernstein JD, Liang CS, Goldscher DA, Freeman I, Kukin ML, Kinhal V, Udelson JE, Klapholz M, Gottlieb SS, Pearle D, Cody RJ, Gregory JJ, Kantrowitz NE, LeJemtel TH, Young ST, Lukas MA, Shusterman NH, for the PRECISE Study Group. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure: the PRECISE trial. Circulation. 1996;94:2793-2799.
89. Colucci WS, Packer M, Bristow MR, Gilbert EM, Cohn JN, Fowler MB, Krueger S, Hershberger RE, Uretsky BF, Bowers JA, Sackner-Bernstein JD, Young ST, Holcslaw TL, Lukas MA, for the US Carvedilol Heart Failure Study Group. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation. 1996;94:2800-2806.
90. Cohn JN, Fowler MB, Bristow MR, Colucci WS, Gilbert EM, Kinal V, Krueger SK, LeJemtel T, Narahara KA, Packer M, for the Carvedilol Heart Failure Study Group. Effect of carvedilol in severe chronic heart failure. J Am Coll Cardiol. 1996;27:169A. Abstract.
91. Australia-New Zealand Heart Failure Research Collaborative Group. Effects of carvedilol, a vasodilator-β-blocker, in patients with congestive heart failure due to ischemic heart disease. Circulation. 1995; 92:212-218.
92. Australia/New Zealand Heart Failure Research Collaborative Group. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet. 1997;349: 375-380.
93. Metra M, Nardi M, Giubbini R, Dei Cas L. Effects of short- and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 1994;24: 1678-1687.
94. Packer M. Effects of β-blockade on survival of patients with chronic heart failure. Am J Cardiol. 1997;80:46L-54L.
95. Pfeffer MA, Stevenson LW. β-adrenergic blockers and survival in heart failure. N Engl J Med. 1996;334:1396-1397.
96. Cleland JG, Swedberg K. Carvedilol for heart failure, with care. Lancet. 1996;347:1199-1201.
97. Chatterjee K. Heart failure therapy in evolution. Circulation. 1996;94: 2689-2693.
98. Coreg finally approved in the US. SCRIP World Pharmaceutical News 2238:17. June 6, 1997.
99. Bristow MR, Colucci WS, Fowler MB, Gilbert EM, Lukas MA, Young ST, Hershberger RE, Adams S, Melman H, Liang C-S. Effect of carvedilol on survival and hospitalization in patients with ischemic or non-ischemic cardiomyopathy. Circulation. 1996;94(suppl I)I-338. Abstract.
100. Fisher ML, Gottlieb SS, Plotnick GD, Greenberg NL, Patten RD, Bennett SK, Hamilton BP. Beneficial effects of metoprolol in heart failure associated with coronary artery disease: a randomized trial. J Am Coll Cardiol. 1994;23:943-950.
101. Bristow MR, Gilbert EM, Packer M, Colucci WS, Lukas MA, Court M, Fowler MB, Cohn JN. Effects of carvedilol in elderly patients with chronic heart failure. Circulation. 1997;96(suppl I):I-577. Abstract.
102. Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger R, Kubo SH, Narahara KA, Robertson AD, Krueger S. Effect of carvedilol on LV function and mortality in diabetic versus non-diabetic patients with ischemic or nonischemic dilated cardiomyopathy. Circulation. 1996;94(suppl I):I-664. Abstract.
103. Yancy C, Fowler MB, Colucci WS, Gilbert EM, Lukas MA. Young ST for the US Carvedilol Heart Failure Study Group: response of black heart failure patients to carvedilol. J Am Coll Cardiol. 1997;29:284A.
104. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med. 1987;316:1429-1435.
105. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992;327:685-691.
106. Borchard U. Pharmacokinetics of beta-adrenoceptor blocking agents: clinical significance of hepatic and/or renal clearance. Clin Physiol Biochem. 1990;8(suppl 2):28-34.
107. DeMey C, Brendel E, Enterulig D. Carvedilol increases the systemic bioavailability of oral digoxin. Br J Clin Pharmacol. 1990;29:486-490.
108. Lennard MS, Tucker GT, Woods HF. The polymorphic oxidation of beta-adrenoceptor antagonists: clinical pharmacokinetic considerations. Clin Pharmacokinet. 1986;11:1-17.
109. Zhou HH, Wood AJ. Stereoselective disposition of carvedilol is determined by CYP2D6. Clin Pharmacol Ther. 1995;57:518-524.
110. Lennard MS, Tucker GT, Silas JH, Ramsay LE, Woods HF. Differential stereoselective metabolism of metoprolol in extensive and poor debrisoquin metabolizers. Clin Pharmacol Ther. 1983;34:732-737.
111. Silas JH, McGoutry JC, Lennard MS, Woods HF. Polymorphic metabolism of metoprolol: clinical studies. Eur J Clin Pharmacol. 1985; 28(suppl):85-88.
112. Dutta A, Lanc R, Begg E, Robson R, Sia L, Dukart G, Desjardins R, Yacobi A. Dose proportionality of bisoprolol enantiomers in humans after oral administration of the racemate. J Clin Pharmacol. 1994;34: 829-836.
113. Cheymol G, Woestenborghs R, Snoeck E, Ianucci R, LeMoing JP, Naditch L, Levron JC, Poirier JM. Pharmacokinetic study and cardiovascular monitoring of nebivolol in normal and obese subjects. Eur J Pharmacol. 1997;51:493-498.
114. Swedberg K, Hjalmarson Å, Waagstein F, Wallentin I. Adverse effects of beta-blockade withdrawal in patients with congestive cardiomyopathy. Br Heart J. 1980;44:134-142.
115. Bohm M, Deutsch HJ, Hartmann D, LaRosee K, Stablein A. Improvement of postreceptor events by metoprolol treatment in patients with chronic heart failure. J Am Coll Cardiol. 1997;30:992-996.
116. Tsvetkova TO, Farber DJ, Abraham WT, Kelly P, Eichhorn E, Gilbert EM, Robertson AD, Lindenfeld J, Wolfel EE, Zisman L, Bristow MR. Comparative hemodynamic effects of milrinone and dobutamine in heart failure patients treated chronically with carvedilol. J Card Fail. 1998; 4(suppl 1):36. Abstract.
117. Shakar SF, Abraham WT, Gilbert EM, Robertson AD, Lowes BD, Ferguson DA, Bristow MR. Combined oral positive inotropic and β-blocker therapy for the treatment of refractory class IV heart failure. J Am Coll Cardiol. 1998;31:1336-1340.